Wednesday, April 29, 2020

Trovagene (TROV)

Lead Drug Shows Potential as KRAS inhibitor in Colorectal Cancer

Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company's clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.

Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Trovagene's lead drug effective in 88% of mCRC patients. The company yesterday released interim results from a Phase Ib/II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (mCRC) patients carrying KRAS mutations. Onvansertib is a first-in-class, third generation highly selective inhibitor of PLK1. In the trial, 7 out of eight patients (88%) responded to a drug treatment combination.

Data was presented at AACR 2020 Annual Meeting. The results were presented by Dr. Afsaneh Barzi at the American Association for Cancer Research (AACR) conference. Dr. Barzi was the principal investigator of the study. She is an associate professor of clinical medicine at Keck School of Medicine of USC and medical oncologist at...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report.  NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.